Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Operating Expenses (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Operating Expenses for 8 consecutive years, with $20.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 5.36% to $20.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.2 million, a 1.21% decrease, with the full-year FY2024 number at $94.9 million, up 2.59% from a year prior.
  • Operating Expenses was $20.7 million for Q3 2025 at Precision Biosciences, down from $21.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $47.2 million in Q2 2021 to a low of -$7.0 million in Q4 2022.
  • A 5-year average of $25.6 million and a median of $22.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: crashed 118.81% in 2022, then skyrocketed 414.56% in 2023.
  • Precision Biosciences' Operating Expenses stood at $37.1 million in 2021, then plummeted by 118.81% to -$7.0 million in 2022, then surged by 414.56% to $21.9 million in 2023, then grew by 16.22% to $25.5 million in 2024, then dropped by 18.85% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Operating Expenses are $20.7 million (Q3 2025), $21.9 million (Q2 2025), and $22.1 million (Q1 2025).